Literature DB >> 26473370

Ho:YAG Laser Endopyelotomy is effective for primary and secondary UPJOs.

C C Feng1, G Dong, Z Hang, H Jiang, Q Ding, Y Zhang, Z Wu.   

Abstract

PURPOSE: To assess efficacy of laser endopyelotomy in both primary and secondary ureteropelvic junction obstructions (UPJOs) PATIENTS AND METHODS: Primary category consisted of 10 patients of congenital UPJOs. Secondary category was comprised of UPJOs in 12 status post pyeloplasty, 10 status post lithotomy, 5 status post shock wave lithotripsy, and 10 status post ureteroscopic lithotripsy. Ho:YAG laser endopyelotomy was performed in all subjects. Exclusion criteria included obstructions longer than 2 cm, ipsilateral upper urinary calculi and crossing vasculature.
RESULTS: Mean operation time was 44 min. Average inpatient duration was 1.87 days. No major complication occurred. Follow-ups were at least 12 months. Success rate for single endopyelotomy was 82.5%, leaving 7 patients for a secondary endopyelotomy. Secondary UPJO due to failed pyeloplasty had a predilection of restenosis after endopyelotomy (P = 0.0005) compared to other aetiologies.
CONCLUSIONS: Ho:YAG laser endopyelotomy is a safe and effective approach effective in both primary and secondary UPJO treatments.

Entities:  

Year:  2015        PMID: 26473370

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  2 in total

Review 1.  Minimally Invasive Techniques for the Management of Adult UPJ Obstruction.

Authors:  Marshall C Strother; Phillip Mucksavage
Journal:  Curr Urol Rep       Date:  2016-05       Impact factor: 3.092

2.  Variation in the Use of Open Pyeloplasty, Minimally Invasive Pyeloplasty, and Endopyelotomy for the Treatment of Ureteropelvic Junction Obstruction in Adults.

Authors:  Bruce L Jacobs; Julie C Lai; Rachana Seelam; Janet M Hanley; J Stuart Wolf; Brent K Hollenbeck; John M Hollingsworth; Andrew W Dick; Claude M Setodji; Christopher S Saigal
Journal:  J Endourol       Date:  2017-01-05       Impact factor: 2.942

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.